OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction on Tuesday, September 14th. The shares were bought at an average cost of $3.46 per share, with a total value of $346,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Friday, August 13th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were bought at an average cost of $3.69 per share, with a total value of $369,000.00.
Shares of NASDAQ OPK traded up $0.01 during midday trading on Wednesday, reaching $3.49. 8,877 shares of the company were exchanged, compared to its average volume of 5,440,146. The stock has a market cap of $2.38 billion, a P/E ratio of 31.64 and a beta of 1.75. The stock’s 50-day moving average price is $3.69 and its 200-day moving average price is $3.94. The company has a quick ratio of 1.36, a current ratio of 1.80 and a debt-to-equity ratio of 0.11. OPKO Health, Inc. has a one year low of $3.02 and a one year high of $6.27.
Several research analysts have recently commented on the stock. Barrington Research lowered their target price on shares of OPKO Health from $8.00 to $6.00 and set an “outperform” rating on the stock in a report on Friday, July 30th. LADENBURG THALM/SH SH assumed coverage on shares of OPKO Health in a research note on Monday, June 21st. They issued a “buy” rating and a $7.00 price objective on the stock.
Several large investors have recently modified their holdings of OPK. Quantbot Technologies LP lifted its holdings in OPKO Health by 129.9% in the first quarter. Quantbot Technologies LP now owns 7,294 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 4,122 shares during the period. Baillie Gifford & Co. acquired a new position in OPKO Health in the first quarter valued at $31,000. Eqis Capital Management Inc. acquired a new position in OPKO Health in the second quarter valued at $41,000. Virtu Financial LLC acquired a new position in OPKO Health in the first quarter valued at $48,000. Finally, Profund Advisors LLC acquired a new position in OPKO Health in the first quarter valued at $52,000. Institutional investors own 27.56% of the company’s stock.
About OPKO Health
OPKO Health, Inc, is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment include clinical laboratory operations of BioReference, as well as point-of-care operations.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.